0EL9 Stock Chart & Stats
€2.84
€0.08(2.35%)
At close: 4:00 PM EST
€2.84
€0.08(2.35%)
Day’s Range― - ―
52-Week Range€2.55 - €7.76
Previous CloseN/A
Volume52.00
Average Volume (3M)23.00
Market Cap
€13.50M
Enterprise Value€7.55
Total Cash (Recent Filing)€9.26M
Total Debt (Recent Filing)€2.48M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Apr 27, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding5,444,998
10 Day Avg. Volume26
30 Day Avg. Volume23
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.80
Price to Sales (P/S)1.05
P/FCF Ratio12.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€15.00M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageDebt-to-equity of about 0.13 and substantial equity relative to assets provide a durable financial cushion. Low leverage should preserve borrowing capacity and reduce balance-sheet risk while management works to restore profitability.
Recent Positive Cash GenerationOperating cash flow and free cash flow were positive in both 2024 and 2025, showing that the business can convert operations into cash even during a loss year. This supports ongoing investment and liquidity, although consistency remains important.
Diversified Medical-Device ModelThe company spans development, manufacturing and distribution across consumer health and professional healthcare channels. This integrated model and exposure to multiple medical-device use cases can support customer reach and reduce dependence on one route to market.
Bears Say
Return To Operating Losses2025 brought a return to negative operating profit and net margin after profitable years in 2022–2024. Persistent losses would weaken retained capital and limit the company’s ability to fund growth without relying on external financing.
Uneven Revenue TrendRevenue was volatile and generally declined from 2020 through 2024, with only a small rebound in 2025. An uneven top-line trajectory makes planning harder and suggests that demand or product mix has not yet produced durable growth.
Volatile Cash FlowFree cash flow remained positive in 2025 but dropped sharply from 2024, while the cycle included negative free cash flow in 2021–2023. This variability can constrain investment capacity and makes recent cash generation less dependable as a long-term strength.
0EL9 FAQ
What was Geratherm Medical AG’s price range in the past 12 months?
Geratherm Medical AG lowest share price was €2.55 and its highest was €7.76 in the past 12 months.
What is Geratherm Medical AG’s market cap?
Geratherm Medical AG’s market cap is €13.50M.
When is Geratherm Medical AG’s upcoming earnings report date?
Geratherm Medical AG’s upcoming earnings report date is Apr 27, 2027 which is in 241 days.
How were Geratherm Medical AG’s earnings last quarter?
Geratherm Medical AG released its earnings results on Aug 27, 2026. The company reported -€0.042 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Geratherm Medical AG overvalued?
According to Wall Street analysts Geratherm Medical AG’s price is currently Overvalued.
Does Geratherm Medical AG pay dividends?
Geratherm Medical AG does not currently pay dividends.
What is Geratherm Medical AG’s EPS estimate?
Geratherm Medical AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Geratherm Medical AG have?
Geratherm Medical AG has 5,444,998 shares outstanding.
What happened to Geratherm Medical AG’s price movement after its last earnings report?
Geratherm Medical AG reported an EPS of -€0.042 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Geratherm Medical AG?
Currently, no hedge funds are holding shares in GB:0EL9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geratherm Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.37%
12-Months-Change
Fundamentals
Return on Equity
4.14%
Trailing 12-Months
Asset Growth
-8.91%
Trailing 12-Months
Company Description
Geratherm Medical AG
Geratherm Medical AG, a German-based medical technology enterprise, organizes its operations across four primary divisions: Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems. The Healthcare Diagnostic unit offers a range of items including clinical thermometers, blood pressure monitors, and various self-test diagnostic products designed for women, such as pregnancy tests, chlamydia screens, urinary tract infection indicators, diverse ovulation solutions, and pH tests. Its Respiratory segment is dedicated to the development and production of equipment primarily for diagnosing pulmonary and cardiopulmonary function. Under the LMT brand, the Medical Warming Systems division manufactures MRI-compatible incubators for premature and newborn infants. The Cardio/Stroke segment provides analytical products aimed at assessing stroke risk by detecting atrial fibrillation. The company markets its healthcare solutions via pharmacies, hospitals, and clinics, and successfully exports its merchandise to approximately 60 nations worldwide. Established in 1990, Geratherm Medical AG's headquarters are situated in Geschwenda, Germany.
Technical Analysis
Draegerwerk AG & Co. KGaA
―
MeVis Medical Solutions
―
STRATEC Biomedical
―
Siemens Healthineers AG
―
elexxion AG
―